EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Genomic Patterns of Well-Differentiated Pancreatic Neuroendocrine Tumors (NETs) Identify Sub-Sets for Rational Therapeutic Targeting

Ioannis A Voutsadakis iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27188002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Ioannis A Voutsadakis. Beteiligte Einrichtung: Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Neuroendocrine Tumors. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The natural history of pancreatic neuroendocrine tumors (NETs) can span decades of slow progression, but it is unpredictable, with a more aggressive course also being common. The two clinical biomarkers currently used to define the grade of a tumor, the Ki67 index and the mitotic index, are not able to fully capture the course of individual patients. This creates an unmet need to discover better prognostic biomarkers to inform therapeutic decisions, as well as therapies with overall survival benefit. Two genomic series of pancreatic NETs were examined to discover sub-sets with divergent characteristics. Primary data were downloaded from the cBioportal cancer genomics portal and analyzed at the individual sample level. Pancreatic NET patients without MEN1/DAXX/ATRX mutations were younger than NET patients with any of these mutations. Pancreatic NETs had consistently low tumor mutation burden but were heterogeneous in their Fraction Genome Altered (FGA), a metric of chromosomal instability (CIN), with one group presenting high FGA and another possessing low to intermediate FGA. FGA did not correlate with Ki67, but high FGA was most prevalent in cases with mutations in MEN1 and DAXX or ATRX. TSC2 mutations were significantly more prevalent in the group with high FGA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsNeuroendocrine TumorsHumansMutationX-linked Nuclear ProteinGenomicsMaleBiomarkers, TumorCo-Repressor ProteinsFemaleKi-67 AntigenChromosomal InstabilityMolecular ChaperonesMiddle AgedProto-Oncogene Proteins

Stichwörter der Autor:innen

ATRXDAXXMEN1chromosomal instabilityneuroendocrine neoplasms

Substanzen

X-linked Nuclear ProteinATRX protein, humanBiomarkers, TumorDAXX protein, humanMEN1 protein, humanCo-Repressor ProteinsKi-67 AntigenMolecular ChaperonesProto-Oncogene Proteins

Autor:innen und Institutionen

  • Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA.
  • Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.
  • Section of Internal Medicine, Division of Clinical Sciences, Northern Ontario School of Medicine, Sudbury, ON P3E 2C6, Canada.

ORCID-Profile: Ioannis A Voutsadakis

Zitieren

APA

Voutsadakis, I. A. (2026). The Genomic Patterns of Well-Differentiated Pancreatic Neuroendocrine Tumors (NETs) Identify Sub-Sets for Rational Therapeutic Targeting. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188002

Vancouver

Voutsadakis IA. The Genomic Patterns of Well-Differentiated Pancreatic Neuroendocrine Tumors (NETs) Identify Sub-Sets for Rational Therapeutic Targeting. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188002

BibTeX
@article{Voutsadakis2026,
  author = {Voutsadakis, Ioannis A},
  title = {The Genomic Patterns of Well-Differentiated Pancreatic Neuroendocrine Tumors (NETs) Identify Sub-Sets for Rational Therapeutic Targeting},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27188002}
}
Kostenlos starten →